308 related articles for article (PubMed ID: 24718366)
21. New insights into the global burden of noroviruses and opportunities for prevention.
Hall AJ; Glass RI; Parashar UD
Expert Rev Vaccines; 2016 Aug; 15(8):949-51. PubMed ID: 27142965
[No Abstract] [Full Text] [Related]
22. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
Malm M; Tamminen K; Vesikari T; Blazevic V
Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
[TBL] [Abstract][Full Text] [Related]
23. Vaccines against norovirus: state of the art trials in children and adults.
Baehner F; Bogaerts H; Goodwin R
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S136-S139. PubMed ID: 27130672
[TBL] [Abstract][Full Text] [Related]
24. Progress on norovirus vaccine research: public health considerations and future directions.
Mattison CP; Cardemil CV; Hall AJ
Expert Rev Vaccines; 2018 Sep; 17(9):773-784. PubMed ID: 30092671
[TBL] [Abstract][Full Text] [Related]
25. Norovirus Vaccine: Priorities for Future Research and Development.
Esposito S; Principi N
Front Immunol; 2020; 11():1383. PubMed ID: 32733458
[TBL] [Abstract][Full Text] [Related]
26. Noroviruses: epidemiology, immunity and prospects for prevention.
Pringle K; Lopman B; Vega E; Vinje J; Parashar UD; Hall AJ
Future Microbiol; 2015; 10(1):53-67. PubMed ID: 25598337
[TBL] [Abstract][Full Text] [Related]
27. Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotype.
Tamminen K; Huhti L; Vesikari T; Blazevic V
Viral Immunol; 2013 Apr; 26(2):167-70. PubMed ID: 23438469
[TBL] [Abstract][Full Text] [Related]
28. Recent advancements in combination subunit vaccine development.
Tan M; Jiang X
Hum Vaccin Immunother; 2017 Jan; 13(1):180-185. PubMed ID: 27649319
[TBL] [Abstract][Full Text] [Related]
29. A dual vaccine candidate against norovirus and hepatitis E virus.
Wang L; Cao D; Wei C; Meng XJ; Jiang X; Tan M
Vaccine; 2014 Jan; 32(4):445-52. PubMed ID: 24291540
[TBL] [Abstract][Full Text] [Related]
30. A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus.
Xia M; Wei C; Wang L; Cao D; Meng XJ; Jiang X; Tan M
Vaccine; 2016 Feb; 34(7):905-13. PubMed ID: 26778421
[TBL] [Abstract][Full Text] [Related]
31. Norovirus infections and seroprevalence of genotype GII.4-specific antibodies in a Spanish population.
Carmona-Vicente N; Fernández-Jiménez M; Ribes JM; Téllez-Castillo CJ; Khodayar-Pardo P; Rodríguez-Diaz J; Buesa J
J Med Virol; 2015 Apr; 87(4):675-82. PubMed ID: 25655810
[TBL] [Abstract][Full Text] [Related]
32. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.
Ma Y; Li J
J Virol; 2011 Mar; 85(6):2942-52. PubMed ID: 21228240
[TBL] [Abstract][Full Text] [Related]
33. A split NanoLuc complementation-based human norovirus-like particle entry assay facilitates evaluation of anti-norovirus antibodies in live cells.
Qiao W; Wang S; Zhang C; Huang Z
Antiviral Res; 2022 Jan; 197():105231. PubMed ID: 34965447
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.
Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY
Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine.
Chen W; Kang T; Yuan R; Shao C; Jing S
Biotechnol Lett; 2020 Jul; 42(7):1211-1218. PubMed ID: 32088791
[TBL] [Abstract][Full Text] [Related]
36. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.
Tamminen K; Huhti L; Koho T; Lappalainen S; Hytönen VP; Vesikari T; Blazevic V
Immunology; 2012 Jan; 135(1):89-99. PubMed ID: 22044070
[TBL] [Abstract][Full Text] [Related]
37. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM
J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828
[TBL] [Abstract][Full Text] [Related]
38. High yield production of norovirus GII.4 virus-like particles using silkworm pupae and evaluation of their protective immunogenicity.
Masuda A; Man Lee J; Miyata T; Sato S; Masuda A; Taniguchi M; Fujita R; Ushijima H; Morimoto K; Ebihara T; Hino M; Kakino K; Mon H; Kusakabe T
Vaccine; 2023 Jan; 41(3):766-777. PubMed ID: 36528444
[TBL] [Abstract][Full Text] [Related]
39. Epidemiologic challenges in norovirus vaccine development.
Hallowell BD; Parashar UD; Hall AJ
Hum Vaccin Immunother; 2019; 15(6):1279-1283. PubMed ID: 30481104
[TBL] [Abstract][Full Text] [Related]
40. Norovirus.
Robilotti E; Deresinski S; Pinsky BA
Clin Microbiol Rev; 2015 Jan; 28(1):134-64. PubMed ID: 25567225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
